Key Points
- COO Cheryl Gault sold 2,014 shares of Rapport Therapeutics on March 5 at an average price of $28.93 for $58,265, and now owns 169,914 shares (a 1.17% reduction) valued at about $4.92 million.
- Institutional investors have been adding to positions: Baker Bros. raised its stake to 1,547,090 shares (up 181.2%), Capital International holds 3,402,529 shares, and UBS AM increased its position by 265.9%, indicating significant institutional accumulation.
- Analyst sentiment is broadly positive with eight Buys and one Sell, a consensus rating of "Moderate Buy" and a consensus target price of $50.80 (notable targets: $43 from Wells Fargo and $47 from BTIG).
Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) COO Cheryl Gault sold 2,014 shares of the firm's stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $28.93, for a total value of $58,265.02. Following the completion of the transaction, the chief operating officer owned 169,914 shares in the company, valued at $4,915,612.02. The trade was a 1.17% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Rapport Therapeutics Stock Up 1.0%
Shares of RAPP opened at $30.54 on Tuesday. Rapport Therapeutics, Inc. has a 52-week low of $7.73 and a 52-week high of $42.27. The stock has a market cap of $1.46 billion, a PE ratio of -11.27 and a beta of 1.50. The firm's fifty day moving average is $28.16 and its two-hundred day moving average is $26.76.
Hedge Funds Weigh In On Rapport Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of RAPP. Baker BROS. Advisors LP raised its position in shares of Rapport Therapeutics by 181.2% during the 3rd quarter. Baker BROS. Advisors LP now owns 1,547,090 shares of the company's stock valued at $45,949,000 after buying an additional 997,000 shares during the period. Vestal Point Capital LP purchased a new position in Rapport Therapeutics in the third quarter worth approximately $28,215,000. Polar Capital Holdings Plc acquired a new stake in Rapport Therapeutics during the third quarter worth $27,887,000. Capital International Investors increased its stake in Rapport Therapeutics by 30.7% during the third quarter. Capital International Investors now owns 3,402,529 shares of the company's stock worth $101,055,000 after acquiring an additional 800,000 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Rapport Therapeutics by 265.9% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 892,258 shares of the company's stock valued at $26,500,000 after purchasing an additional 648,378 shares during the period.
Analyst Upgrades and Downgrades
A number of analysts have commented on RAPP shares. The Goldman Sachs Group reiterated a "buy" rating on shares of Rapport Therapeutics in a report on Friday, December 19th. Wells Fargo & Company initiated coverage on Rapport Therapeutics in a report on Monday, February 2nd. They set an "overweight" rating and a $43.00 target price on the stock. BTIG Research reaffirmed a "buy" rating and issued a $47.00 price target on shares of Rapport Therapeutics in a report on Monday. Citigroup reiterated a "market outperform" rating on shares of Rapport Therapeutics in a research report on Thursday, January 8th. Finally, TD Cowen reissued a "buy" rating on shares of Rapport Therapeutics in a research note on Monday. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $50.80.
Check Out Our Latest Report on Rapport Therapeutics
Rapport Therapeutics Company Profile
(
Get Free Report)
Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.
Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
